ASCO 2020：11项中国研究成果入选口头报告，17项Poster报告

受全球上新冠疫情影响，延后于5年末29日~6年末2日在芝加哥闭幕的美国诊疗学时会（ASCO）讨论时会今年将首次以中央线上形式协办，这是目前最大规模的中央线上盛时会。今天，开时会的简述题目公布，共103个sessions，之中国人共有11项深入研究荣膺口头报告，17项荣膺Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

巯基替尼或拉帕替尼加卡培他滨用做HER2+转回功能性肺乳腺癌（PHOEBE）：一项III期随机飞行测试。

艺术节：转回功能性肺乳腺癌

译者：之中国人医学科学院病房徐兵河副教授、马飞副教授，武汉大学附属病房胡夕春副教授等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴功能性肺乳腺癌常规用药后卡培他滨依靠节拍化疗的III期飞行测试（SYSUCC-001）。

艺术节：肺乳腺癌—暂时性/区外/专用用药

译者：之中山大学保健该之中心王树森副教授等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用转回功能性小脑的表型特征来计算小脑脊液之中循环DNA检测的概率: 上新方法对抗来由取胜

艺术节：上新方法解决来由问题

译者：徐美芹 徐德兰等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为晚期脾线粒体乳腺癌的一中央线用药：一项停止使用首页、随机、多该之中心II/III期飞行测试。

艺术节：小肠乳腺癌—食道食管、血栓和实乃

译者：南京大学华西病房毕锋副教授、之中国人当权者解放军二七病房秦叔逵副教授等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之中国人晚期脾乳腺癌病患者阿帕替尼西段用药：一项随机、低剂量依此、双盲III期深入研究

艺术节：小肠乳腺癌—食道食管、血栓和实乃

译者：之中国人当权者解放军二七病房秦叔逵副教授、南京大学华西病房徐秋副教授等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

晚期复发功能性膀胱乳腺癌二次线粒体减灭术的一项随机III期飞行测试：SOC1 / SGOG-OV2。

讲座：医学乳腺癌症

译者：武汉大学附属之中山病房臧荣余副教授等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳腺癌根治功能性子宫输卵管后专用用药之中的序贯放化疗对比单独前列腺癌或不间断放化疗（STARS深入研究）：一项随机、依此、停止使用首页的III期飞行测试。

开时会：医学乳腺癌症

译者：之中山大学保健该之中心凌云副教授、刘继红副教授等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专用吉非替尼对比化疗用做可切除的EGFR突变的N1-N2期NSCLC-随机III期诊疗飞行测试的再次总体肉食动物系统性。

讲座：心脏病症—非小线粒体暂时性-区外/小线粒体/其他胸部

译者：广东省当权者病房吴一龙副教授等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡转回非小线粒体心脏病症病患者一中央线色氨酸激酶药物牵头或不牵头积极前中央线暂时性前列腺癌：III期停止使用首页诊疗随机飞行测试（SINDAS）的之初结果（NCT02893332）。

讲座：心脏病症-非小线粒体转回

译者：四川省当权者病房曾铭副教授等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序功能性死亡-1（PD-1）的人源化IgG4HIV牵头阿昔替尼用做转回功能性发炎癌症病患者的Ib期深入研究的总肉食动物期和生物标志物系统性。

讲座：癌症/皮肤乳腺癌

译者：北京大学病房郭军、盛锡楠副教授等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全功能性和结果：通用CAR-T线粒体首次人体飞行测试用药复发/难治功能性T线粒体急功能性淋巴线粒体白血病（r/r T-ALL）的安全功能性和。开时会：联合开发之中的用药技术-免疫用药。译者：王欣欣等简述：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在晚期食管点状线粒体乳腺癌病患者之中的应用于：一项随机的停止使用首页II期飞行测试（ORIENT-2）。开时会：小肠乳腺癌-食道食管乳腺癌、血栓乳腺癌和实乃道乳腺癌译者：徐建明副教授等简述：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异功能性CAR-T线粒体对滋养母线粒体瘤的根除功能性用药开时会：之中枢神经系统译者：代红久、孙斌、杨东、徐晖、郑晶晶、魏佳、杨旭东简述：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在晚期错配修复毛病病患者之中的应用于开时会：联合开发之中的用药学-免疫用药译者：沈琳副教授等简述：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 其时会CD7-CART用药复发/难治功能性ACUTE淋巴线粒体白血病/淋巴瘤的首度人体诊疗飞行测试开时会: 联合开发功能性用药学-免疫用药译者简介：张明志，杨林等简述：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 罗勒替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头应用于做晚期实体瘤病患者的Ib期深入研究开时会：发展功能性用药学----大分子靶向药物和病理学译者：龚继芳，沈琳副教授等简述：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头抗病毒和nedaplatin用药复发功能性或转回功能性食管点状线粒体乳腺癌（ESCC）病患者的II期深入研究。开时会：小肠乳腺癌-食道食管、血栓和实乃道乳腺癌的深入研究译者：王志强，徐玉红，王德申，王凤华，任超，谭琼 王志强、徐玉红、王德深、王凤华、任超、谭琼简述：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开时会：小肠乳腺癌-食道食管乳腺癌、血栓乳腺癌和实乃管乳腺癌的西段用药译者：宋艳等简述：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种粪便外体内环RNA数据集用做初始活检时检测高等级乳腺癌的粪便外体内环RNA数据集：一项多该之中心的回顾功能性深入研究开时会：泌尿系统生殖系统乳腺癌症----乳腺癌、睾丸乳腺癌和乳腺癌译者简介：Liaoyuan Li等简述：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 暂时性晚期宫颈乳腺癌并发化疗后的专用化疗开时会: 医学乳腺癌症译者简介： 徐珉珉等简述：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药甲状腺滋养功能性乳腺癌的相关功能性：基于ALTER01031飞行测试的系统性。时会衹：躯干译者：天津市病房来由练副教授简述：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、较小和年龄对安洛替尼用药后病患者结局的影响: ALTER01031的亚组系统性开时会：躯干译者：天津市病房来由练副教授简述：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA系统性计算I-IIIA期非小线粒体心脏病症（NSCLC）病患者术后复发: GASTO1035和GASTO1018的结果开时会：心脏病症-非小线粒体暂时性-区外功能性/小线粒体/小线粒体/其他胸科乳腺癌症译者：Si-Yu Wang等简述：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体心脏病症（NSCLC）之中EGFR色氨酸激酶药物的上新型细菌性组态开时会:心脏病症-非小线粒体转回功能性心脏病症译者简介：杨昕，金艾利，满宇，欧秋香，华宝，薛武，杨少，范敏 杨昕、金艾利、满宇、欧秋香、华宝、薛武、杨绍、范敏简述：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1飞行测试之中晚期癌症总肉食动物的替代终点开时会：癌症/皮肤乳腺癌译者：聂润聪，袁书强，徐元芳，陈英波，周志伟 聂润聪、袁书强、徐元芳、陈英波、周志伟简述：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药复发或转回功能性原发功能性恶功能性骨病患者的II期深入研究开时会： 性疾病译者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简述：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞誉安罗替尼在晚期性疾病病患者多中央线用药之中的安全功能性和。开时会：性疾病译者：姚伟涛，王侯强，张鹏，王欣，杜上新辉，田志浩，牛晓颖 姚伟涛、王侯强、张鹏、王鑫、杜鑫辉、田志超、牛晓英简述：11526标语：414